Hussman Strategic Advisors Inc. Reduces Stock Position in Halozyme Therapeutics, Inc. $HALO

Hussman Strategic Advisors Inc. decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 62.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,500 shares of the biopharmaceutical company’s stock after selling 52,500 shares during the quarter. Hussman Strategic Advisors Inc.’s holdings in Halozyme Therapeutics were worth $2,310,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. DLD Asset Management LP acquired a new position in Halozyme Therapeutics during the second quarter worth $650,250,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Halozyme Therapeutics by 127.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock worth $132,192,000 after buying an additional 1,425,674 shares during the last quarter. LSV Asset Management boosted its position in shares of Halozyme Therapeutics by 40.2% in the 2nd quarter. LSV Asset Management now owns 1,255,240 shares of the biopharmaceutical company’s stock worth $65,298,000 after buying an additional 360,049 shares in the last quarter. Royal London Asset Management Ltd. grew its stake in Halozyme Therapeutics by 122.3% in the 2nd quarter. Royal London Asset Management Ltd. now owns 1,101,912 shares of the biopharmaceutical company’s stock valued at $57,321,000 after acquiring an additional 606,236 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $51,295,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on HALO shares. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. TD Cowen raised their price target on Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Citizens Jmp upped their price objective on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. Finally, Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 6th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $78.80.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $70.22 on Wednesday. The company has a market cap of $8.26 billion, a P/E ratio of 14.78, a P/E/G ratio of 0.31 and a beta of 0.94. The business has a fifty day simple moving average of $68.76 and a 200-day simple moving average of $68.20. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $79.50. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The firm had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm’s quarterly revenue was up 22.1% on a year-over-year basis. During the same period last year, the company earned $1.27 EPS. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Cortney Caudill sold 4,263 shares of Halozyme Therapeutics stock in a transaction on Saturday, November 1st. The shares were sold at an average price of $65.19, for a total transaction of $277,904.97. Following the completion of the transaction, the chief operating officer owned 12,737 shares in the company, valued at approximately $830,325.03. This trade represents a 25.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 45,661 shares of company stock worth $3,139,257. 2.90% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.